Drug
SB1518
SB1518 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
3
60%
Ph phase_2
2
40%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
completed480%
terminated120%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_2
SB1518 for Patients With Myelodysplastic Syndrome (MDS)
NCT01436084
completedphase_1
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
NCT00741871
completedphase_1
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
NCT00745550
completedphase_1
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
NCT00719836
completedphase_2
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
NCT01263899
Clinical Trials (5)
Showing 5 of 5 trials
NCT01436084Phase 2
SB1518 for Patients With Myelodysplastic Syndrome (MDS)
NCT00741871Phase 1
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
NCT00745550Phase 1
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
NCT00719836Phase 1
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
NCT01263899Phase 2
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5